Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04931901
Other study ID # StimpodVSDatex-Ohmeda
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 6, 2021
Est. completion date December 31, 2023

Study information

Verified date November 2022
Source Universitair Ziekenhuis Brussel
Contact Evelien Vandeurzen, MSC
Phone 024749237
Email evelien.vandeurzen@uzbrussel.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

After anesthesia is induced, 2 EMG TOFF devices will be placed on the patients arms, one on the right arm, the other on the left. There will be a randomization per dominant hand and nondominant hand for the placing of the devices. The devices are the Stimpod NMX450X and the Datex-Ohmeda E-NMT.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (18 years old and above) - undergoing General Anaesthesia for noncardiac surgery requiring the use of a neuromuscular blocking agent. Exclusion Criteria: - Use of different types of neuromuscular blocking agents for the same patient within the same surgical procedure. - Known Neuromuscular diseases/syndromes judged to condition accurate neuromuscular monitoring. - Known acute or chronic hepatic disease.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
EMG TOF device
Use of Stimpod NMX450X as an electromyographic neuromuscular monitor

Locations

Country Name City State
Belgium UZ Brussel Jette Brussel

Sponsors (1)

Lead Sponsor Collaborator
Universitair Ziekenhuis Brussel

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary TOF-ratio (percentage) TOF = Train-of-four. TOF-ratio is the ratio of the fourth muscle response to the first one. This is used to assess neuromuscular transmission. TOF% indicates fade in non-depolarizing block. We are comparing the calculated TOF ratio of the stimpod NMX to the datex-ohmeda E-NMT Up until 120 minutes
Secondary TOF-count (absolute number) TOF count is the actual number of detected muscle responses. The number that is used to calculate the percentage (TOF-ratio). When the TOF count drops below 4 responses, then the TOF% cannot be calculated. We are comparing the detected muscle responses of the stimpod NMX to the datex-ohmeda E-NMT Up until 120 minutes.
See also
  Status Clinical Trial Phase
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Recruiting NCT06381284 - Feasibility of Engaging and Capturing Undiagnosed Myasthenia Gravis Participants Through a Social Media Campaign Paired With a Self-moderated Assessment
Completed NCT03471923 - Non-Motor Features of Cervical Dystonia (CD)
Completed NCT02689544 - Effects of Static Stretching and Dynamic in Flexibility and Performance: Blind and Randomized Clinical Trial N/A
Completed NCT05738200 - Nordic Hamstring Exercise After ACL Reconstruction Reconstruction N/A
Completed NCT03211390 - Using Telemedicine to Improve Spasticity Diagnosis Rates
Completed NCT03209960 - Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity
Completed NCT03250988 - Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Long-Term Care Facility
Active, not recruiting NCT05156320 - Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam Phase 3
Completed NCT03221439 - Cognitive Functional Therapy for Chronic Low Back Pain N/A
Completed NCT03921528 - An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy Phase 2
Active, not recruiting NCT05626855 - Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab-ONYX Phase 3
Recruiting NCT05810272 - Impact of Postprandial 'Exercise Snacks' on Protein and Glucose Metabolism Following a Period of Step Reduction in Older Adults N/A